A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Hernandez-Rivas, José-Ángel (Hospital Universitario Infanta Leonor)
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona)
Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid))
Bellón, José-María (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
García-Sanz, Ramón (Hospital Universitario de Salamanca (IBSAL). CIBERONC e Instituto de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC))
de la Rubia, Javier (Hospital Universitari Doctor Peset (València))
López de la Guía, Ana (Hospital Universitario La Paz (Madrid))
Jímenez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid))
Jarque, Isidro (Hospital Universitario la Fe. CIBERONC)
Iñigo, Belén (Hospital Clínico San Carlos (Madrid))
Dourdil, Victoria (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia))
Cuéllar Pérez-Ávila, Clara (Hospital Universitario 12 de Octubre (Madrid))
Gonzalez, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta)
Hernández, Miguel-Teodoro (Hospital Universitario de Canarias (La Laguna))
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau)
Rodríguez-Otero, Paula (Clínica Universitaria de Navarra. CIMA. IDISNA. CIBERONC)
Silvent, Maialen (Hospital de Donostia (Sant Sebastià, País Basc))
Cabrera, Carmen (Complejo Hospitalario de Cáceres)
Rios, Rafael (Hospital Universitario Virgen de las Nieves (Granada))
Alegre, Adrian (Hospital Universitario de la Princesa. Hospital Universitario Quirónsalud)
Gironella, Mercedes (Hospital Universitari Vall d'Hebron)
Gonzalez, Marta-Sonia (Hospital Universitario de Santiago)
Sureda, Anna (Institut Català d'Oncologia)
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Ocio, Enrique M. (Instituto de Investigación Marqués de Valdecilla)
Krsnik, Isabel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
García, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya))
García-Mateo, Aránzazu (Hospital General de Segovia)
Soler, Joan-Alfons (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Martín Sánchez, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Arguiñano, José M (Complejo Hospitalario de Navarra)
Mateos, M. V. (Instituto de Investigación Biomédica de Salamanca)
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona)
San-Miguel, J (Clínica Universitaria de Navarra. CIMA. IDISNA; CIBERONC)
Lahuerta, J. J (Hospital Universitario 12 de Octubre (Madrid))
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))

Date:	2022
Abstract:	Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13. 8%, and majority of the patients experiencing the first episode before 4 months (11. 1%). 1. 2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8. 2%; intermediate-risk (score 3) 19. 2%; and high-risk (score 4) 28. 3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.
Note:	Altres ajuts: PETHEMA (Spanish Program for the Treatment of Hematological Diseases), Madrid, Spain
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Antibiotic Prophylaxis ; Humans ; Male ; Multiple Myeloma
Published in:	Blood Cancer Journal, Vol. 12 Núm. 4 (april 2022) , p. 68, ISSN 2044-5385

DOI: 10.1038/s41408-022-00652-2
PMID: 35440057

8 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Social and Legal Sciences > Applied Geography Research Group
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles